Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA

Schüttler, Christian G.; Caspari, G.; Jursch, C. A.; Willems, Wulf R.; Gerlich, Wolfram H.; Schaefer, Stephan

doi:10.1016/s0140-6736(99)04719-4

Cited by 116 publications

(91 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Nucleic acid detection methods for HIV and hepatitis C (HCV) have reduced the window period for infectious risk, but may not eliminate transfusion-associated HIV 2 or HCV infections; 3 fatal bacterial infections caused by transfusion of platelet concentrates continue to be reported. 4 To improve the safety of platelet and plasma transfusion, a nucleic acid-targeted photochemical treatment (PCT) using the psoralen compound amotosalen HCl (S-59) and longwavelength ultraviolet A (UVA) light was developed to inactivate viruses, bacteria, and protozoa that may contaminate platelet and plasma components.…”

Section: Introductionmentioning

confidence: 99%

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Rhenen

Gulliksson

Cazenave

et al. 2002

Blood

289

444

View full text Add to dashboard Cite

A nucleic acid-targeted photochemical treatment (PCT) using amotosalen HCl (S-59) and ultraviolet A (UVA) light was developed to inactivate viruses, bacteria, protozoa, and leukocytes in platelet components. We conducted a controlled, randomized, double-blinded trial in thrombocytopenic patients requiring repeated platelet transfusions for up to 56 days of support to evaluate the therapeutic efficacy and safety of platelet components prepared with the buffy coat method using this pathogen inactivation process. A total of 103 patients received one or more transfusions of either PCT test (311 transfusions) or conventional reference (256 transfusions) pooled, leukoreduced platelet components stored for up to 5 days before transfusion. More than 50% of the PCT platelet components were stored for 4 to 5 days prior to transfusion. The mean 1-hour corrected count increment for up to the first 8 test and reference transfusions was not statistically significantly different between treatment groups (13 100 ؎ 5400 vs 14 900 ؎ 6200, P ‫؍‬ .11). By longitudinal regression analysis for all transfusions, equal doses of test and reference components did not differ significantly with respect to the 1-hour (95% confidence interval [CI], ؊3.1 to 6.1 ؋ 10 9 / L, P ‫؍‬ .53) and 24-hour (95% CI, ؊1.3 to 6.5 ؋ 10 9 /L, P ‫؍‬ .19) posttransfusion platelet count. Platelet transfusion dose, pretransfusion storage duration, and patient size were significant covariates (P < .001) for posttransfusion platelet counts. Clinical hemostasis, hemorrhagic adverse events, and overall adverse events were not different between the treatment groups. Platelet components prepared with PCT offer the potential to further improve the safety of platelet transfusion using technology compatible with current methods to prepare buffy coat platelet components. (Blood. 2003;101: 2426-2433)

show abstract

Section: Introductionmentioning

confidence: 99%

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Rhenen

Gulliksson

Cazenave

et al. 2002

Blood

289

444

View full text Add to dashboard Cite

show abstract

“…Thus, in the worst case even viremia at levels below 10 DNA molecules/ml plasma may cause transmission because a therapeutic dose of blood product contains normally much more than 1 ml plasma. Recently, an HCV-transmitting donation was found to contain viral RNA molecules in quantities of 1 to 10/ml [17,18]. The doubling time of HBV concentration in serum is ap- [19].…”

Section: Discussionmentioning

confidence: 99%

Transmission of Hepatitis B Virus 2 Months Prior to Hepatitis Surface Antigen Positivity of Donor Blood

Meisel¹,

Endres²,

Walter³

et al. 2003

Transfus Med Hemother

View full text Add to dashboard Cite

An hepatitis surface antigen(HBsAg)-negative donation transmitted hepatitis B virus (HBV) of the very common genotype A/HBsAg subtype adw2 to the recipient of the erythrocyte concentrate. Two months later the donor became borderline HBsAg-positive. The infectious donation was tested retrospectively by real time PCR and contained approximately 2,000 viral genomes/ml, an amount which would have been well detectable by minipool nucleic acid amplification test (NAT) for HBV DNA at the usual detection limit of 1,000 copies/ml. The case shows that the HBsAg-negative, HBV DNA-positive phase may be longer than previously believed and that HBV DNA screening at a sensitivity achievable by minipool NAT testing would have prevented transmission.

show abstract

“…Nevertheless, HCV RNA-negative donations very rarely prove to be infectious. In 1 published case [60], the plasma of a donor who subsequently seroconverted contained less than 10 genomes/ml. The infectivity of blood products produced from the donation varied: The platelet concentrate was infectious but the red cell concentrate was not [60].…”

Section: Infectious Load Of Starting Materials and Test Methodsmentioning

confidence: 99%

Hepatitis C Virus (HCV)

Fard

Sibrowski

Möllmann

et al. 2003

Transfus Med Hemother

View full text Add to dashboard Cite

1.1 Characteristics of HCV HCV is the sole virus species of the genus Hepacivirus which, together with the genera Flavivirus and Pestivirus, constitutes the Flaviviridae family of viruses [1, 2]. The genera Hepacivirus and Pestivirus are structurally and biologically more closely related to one another than to the genus Flavivirus. Unlike Flavivirus, neither requires arthropods as vectors, and both may cause persistent infections in mammals. HCV is similar to the GB virus type B (GBV-B) that causes hepatitis in tamarin monkeys. Less closely related to HCV are GBV-A in various New World monkeys and GBV-C in humans [2], which to date has no known pathogenicity. The virus particles of Flaviviridae are surrounded by a lipid envelope in which at least two glycosylated surface proteins are anchored: E1 and E2 in the case of the genera Hepacivirus and Pestivirus, M and E in the case of the genus Flavivirus. (Pestiviruses additionally contain an E^rns). The viral envelope encloses a core particle formed from core protein and the single- stranded genome RNA with approximately 9,600 bases (in the case of HCV). Since only modest amounts of HCV can be isolated from plasma, the structure of the virus particles has not yet been exhaustively investigated. The hypothetical model in figure 1 has been inferred from knowledge about other Flaviviridae. ...

show abstract

Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA

Cited by 116 publications

References 4 publications

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Transmission of Hepatitis B Virus 2 Months Prior to Hepatitis Surface Antigen Positivity of Donor Blood

Hepatitis C Virus (HCV)

Contact Info

Product

Resources

About